(Q51190015)

1 April 2018

title

Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. (English)

1 reference

1 April 2018

1 reference

1 reference

1 reference

1

Jason D Wright

1 reference

1 April 2018

author name string

Andrea Hagemann

2

1 reference

1 April 2018

Janet S Rader

3

1 reference

1 April 2018

Dana Viviano

4

1 reference

1 April 2018

Randall K Gibb

5

1 reference

1 April 2018

Lori Norris

6

1 reference

1 April 2018

David G Mutch

7

1 reference

1 April 2018

Matthew A Powell

8

1 reference

1 April 2018

language of work or name

English

0 references

publication date

1 July 2006

1 reference

1 April 2018

published in

Cancer

1 reference

1 April 2018

volume

107

1 reference

1 April 2018

issue

1

1 reference

1 April 2018

page(s)

83-89

1 reference

1 April 2018

Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Optimal sequencing in the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

The influence of microvessel density on ovarian carcinogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Intestinal perforation secondary to paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Chylous ascites following para-aortic lymphadenectomy: a case report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

The biology of vascular endothelial growth factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21969

7 January 2021

Identifiers

DOI

10.1002/CNCR.21969

1 reference

1 April 2018

PubMed ID

16736514

1 reference

1 April 2018